Who Owns Allogene Therapeutics Stock?
NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 82.62%
- Held by insiders
- 11.03%
- Institutional holders
- 280
- Institutions 82.6%
- Insiders 11.0%
- Public and other 6.3%
Who owns Allogene Therapeutics stock?
Institutional investors own about 82.6% of Allogene Therapeutics's shares, spread across 280 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 11.03% of ALLO.
The largest institutional holders are Blackrock Inc. (8.73%), Frazier Life Sciences Management, L.P. (6.50%) and Pfizer Inc (6.38%). Together, the top 10 institutions control 50.1% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their ALLO positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ALLO
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 30.15M | 8.73% | +57.9% |
| Frazier Life Sciences Management, L.P. | 22.45M | 6.50% | +491.2% |
| Pfizer Inc | 22.03M | 6.38% | 0.0% |
| State Street Corporation | 19.03M | 5.51% | +119.7% |
| TPG GP A, LLC | 18.72M | 5.42% | 0.0% |
| Sio Capital Management, LLC | 13.32M | 3.86% | +100.0% |
| Primecap Management Company | 13.12M | 3.80% | +56.6% |
| Vanguard Capital Management LLC | 12.17M | 3.52% | +75.8% |
| FMR, LLC | 12.01M | 3.48% | +655.4% |
| Citadel Advisors Llc | 10.09M | 2.92% | +48.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ALLO
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 12.82M | 3.71% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 10.04M | 2.91% |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 9.39M | 2.72% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8.67M | 2.51% |
| iShares Trust-iShares Russell 2000 ETF | 6.81M | 1.97% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.48M | 1.01% |
| T. Rowe Price Health Sciences Fund, Inc. | 3.44M | 1.00% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3.22M | 0.93% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.91M | 0.84% |
| abrdn Life Sciences Investors | 2.73M | 0.79% |
Frequently asked questions
Who is the largest shareholder of Allogene Therapeutics?
Blackrock Inc. is the largest institutional shareholder of ALLO, owning 8.73% of shares outstanding (30.15M shares) as of its latest 13F filing.
What percentage of Allogene Therapeutics is owned by institutions?
Institutions own about 82.6% of ALLO shares and 92.9% of the public float.
How much of Allogene Therapeutics do insiders own?
Insiders, such as officers and directors, own about 11.03% of ALLO shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.